Journal Article
. 2011 Jun;130(2).
doi: 10.1007/s10549-011-1628-6.

Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care

Jennifer S Haas 1 Su-Ying Liang  Michael J Hassett  Stephen Shiboski  Elena B Elkin  Kathryn A Phillips  
Affiliations
  • PMID: 21681446
  •     29 References
  •     4 citations

Abstract

As gene expression profile (GEP) testing for breast cancer may provide additional prognostic information to guide the use of adjuvant chemotherapy, we examined the association between GEP testing and use of chemotherapy, serious chemotherapy-related adverse effects, and total charges during the 12 months following diagnosis. Medical record review was conducted for women age 30-64 years, with incident, non-metastatic, invasive breast cancer diagnosed 2006-2008 in a large, national health plan. Of 534 patients, 25.8% received GEP testing, 68.2% received chemotherapy, and 10.5% experienced a serious chemotherapy-related adverse effect. GEP testing was most commonly used in women at moderate clinical risk of recurrence (52.0 vs. 25.0% of low-risk women and 5.5% of high-risk). Controlling for the propensity to receive GEP testing, women who had GEP were less likely to receive chemotherapy (propensity adjusted odds ratio, 95% confidence interval 0.62, 0.39-0.99). Use of GEP was associated with more chemotherapy use among women at low risk based on clinical characteristics (OR = 42.19; CI 2.50-711.82), but less use among women with a high risk based on clinical characteristics (OR = 0.12; CI 0.03-0.47). Use of GEP was not associated with chemotherapy for the moderate risk group. There was no significant relationship between GEP use and either serious chemotherapy-associated adverse effects or total charges. While GEP testing was associated with an overall decrease in adjuvant chemotherapy, we did not find differences in serious chemotherapy-associated adverse events or charges during the 12 months following diagnosis.

The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort.
Foluso O Ademuyiwa, Austin Miller, +5 authors, Sunil Badve.
Breast Cancer Res Treat, 2011 Jan 05; 126(3). PMID: 21197567
Tradeoffs of using administrative claims and medical records to identify the use of personalized medicine for patients with breast cancer.
Su-Ying Liang, Kathryn A Phillips, +4 authors, Jennifer S Haas.
Med Care, 2011 Mar 23; 49(6). PMID: 21422962    Free PMC article.
Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.
John Hornberger, Leon E Cosler, Gary H Lyman.
Am J Manag Care, 2005 May 19; 11(5). PMID: 15898220
Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer.
Daphne T Tsoi, Miho Inoue, +2 authors, Kathleen I Pritchard.
Oncologist, 2010 Apr 28; 15(5). PMID: 20421264    Free PMC article.
Gene expression profiling and breast cancer care: what are the potential benefits and policy implications?
Nina Oestreicher, Scott D Ramsey, +4 authors, David L Veenstra.
Genet Med, 2005 Jul 19; 7(6). PMID: 16024969
Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer.
Michael J Hassett, A James O'Malley, +2 authors, Craig C Earle.
J Natl Cancer Inst, 2006 Aug 17; 98(16). PMID: 16912263
Highly Cited.
Cancer statistics, 2010.
Ahmedin Jemal, Rebecca Siegel, Jiaquan Xu, Elizabeth Ward.
CA Cancer J Clin, 2010 Jul 09; 60(5). PMID: 20610543
Highly Cited.
Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection.
Shelly S Lo, Patricia B Mumby, +8 authors, Kathy S Albain.
J Clin Oncol, 2010 Jan 13; 28(10). PMID: 20065191
Highly Cited.
Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods.
Thérèse A Stukel, Elliott S Fisher, +3 authors, Marian J Vermeulen.
JAMA, 2007 Jan 18; 297(3). PMID: 17227979    Free PMC article.
Highly Cited.
Oncotype DX tumor gene expression profiling in stage II colon cancer. Application: prognostic, risk prediction.
Elizabeth M Webber, Jennifer S Lin, Evelyn P Whitlock.
PLoS Curr, 2010 Sep 30; 2. PMID: 20877447    Free PMC article.
Evaluation of trends in the cost of initial cancer treatment.
Joan L Warren, K Robin Yabroff, +3 authors, Martin L Brown.
J Natl Cancer Inst, 2008 Jun 12; 100(12). PMID: 18544740    Free PMC article.
Highly Cited.
Economic implications of 21-gene recurrence score assay: US multicenter experience.
John Hornberger, Gary H Lyman, Rebecca Chien.
J Clin Oncol, 2010 May 26; 28(22). PMID: 20498396
Systematic review: gene expression profiling assays in early-stage breast cancer.
Luigi Marchionni, Renee F Wilson, +4 authors, Steven N Goodman.
Ann Intern Med, 2008 Feb 07; 148(5). PMID: 18252678
Systematic Review.
Payers Try New Approaches To Manage Molecular Diagnostics: Some payers require prior authorization for molecular diagnostic testing and some don't. And some payers are looking at other options.
Biotechnol Healthc, 2010 Oct 01; 7(3). PMID: 22478827    Free PMC article.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
Gene-expression signatures in breast cancer.
Christos Sotiriou, Lajos Pusztai.
N Engl J Med, 2009 Feb 21; 360(8). PMID: 19228622
Highly Cited. Review.
Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies.
Gary H Lyman, Leon E Cosler, Nicole M Kuderer, John Hornberger.
Cancer, 2007 Feb 22; 109(6). PMID: 17311307
Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use.
Karla Kerlikowske, Andrea J Cook, +4 authors, Diana L Miglioretti.
J Clin Oncol, 2010 Jul 21; 28(24). PMID: 20644098    Free PMC article.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Clinical application of the 70-gene profile: the MINDACT trial.
Fatima Cardoso, Laura Van't Veer, +3 authors, Martine J Piccart-Gebhart.
J Clin Oncol, 2008 Feb 09; 26(5). PMID: 18258980
Highly Cited.
Pharmacogenomics, evidence, and the role of payers.
P A Deverka.
Public Health Genomics, 2009 Feb 11; 12(3). PMID: 19204417    Free PMC article.
Physician cost profiling--reliability and risk of misclassification.
John L Adams, Ateev Mehrotra, J William Thomas, Elizabeth A McGlynn.
N Engl J Med, 2010 Mar 20; 362(11). PMID: 20237347    Free PMC article.
Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization.
Shmuel H Klang, Ariel Hammerman, +3 authors, John Hornberger.
Value Health, 2010 Apr 24; 13(4). PMID: 20412544
Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders.
M Soledad Cepeda, Ray Boston, John T Farrar, Brian L Strom.
Am J Epidemiol, 2003 Jul 29; 158(3). PMID: 12882951
Highly Cited.
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.
Lori J Goldstein, Robert Gray, +12 authors, Joseph A Sparano.
J Clin Oncol, 2008 Aug 06; 26(25). PMID: 18678838    Free PMC article.
Highly Cited.
Development of a comorbidity index using physician claims data.
C N Klabunde, A L Potosky, J M Legler, J L Warren.
J Clin Epidemiol, 2001 Jan 09; 53(12). PMID: 11146273
Highly Cited.
National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.
P Eifel, J A Axelson, +11 authors, D Roter.
J Natl Cancer Inst, 2001 Jul 05; 93(13). PMID: 11438563
Highly Cited. Review.
Tissue biomarkers of breast cancer and their association with conventional pathologic features.
L Chung, S Shibli, +4 authors, R C Baxter.
Br J Cancer, 2013 Jan 10; 108(2). PMID: 23299531    Free PMC article.
The value of multigene predictors of clinical outcome in breast cancer: an analysis of the evidence.
Amalia M Issa, Vivek S Chaudhari, Gary E Marchant.
Expert Rev Mol Diagn, 2014 Dec 06; 15(2). PMID: 25479414    Free PMC article.
Review.
Underutilization of gene expression profiling for early-stage breast cancer in California.
Rosemary D Cress, Yingjia S Chen, +2 authors, Kenneth W Kizer.
Cancer Causes Control, 2016 Apr 22; 27(6). PMID: 27097910    Free PMC article.
21-gene recurrence assay in patients receiving intraoperative radiotherapy: are "favorable" characteristics a surrogate for low recurrence?
Bridget A Oppong, Surupa Sen Gupta, +6 authors, Shawna C Willey.
Gland Surg, 2018 Jan 06; 6(6). PMID: 29302485    Free PMC article.